联合用药防治曲霉感染研究进展

摘要/Abstract

摘要：

目前临床上治疗曲霉感染的药物主要有三唑类、多烯类和棘白菌素类，这些药物对控制曲霉感染具有重要作用。然而，随着抗真菌药耐药报道逐年增多，为提高临床疗效和避免曲霉耐药的发生，需要研发新型抗真菌药物或者寻找更为有效的治疗方法。由于研发新药周期长和成本高，越来越多的研究人员着眼于联合用药防治曲霉感染。抗真菌药物之间的联合用药，棘白菌素联合三唑类或多烯类药物可产生协同效应，多烯类联合三唑类药物产生拮抗作用，而抗真菌药物和非抗真菌药之间的联合用药具有较高的临床价值。

中图分类号:

刘洁, 胡小平. 联合用药防治曲霉感染研究进展[J]. 中国真菌学杂志, 2019, 14(2): 124-128.

参考文献

[1] McNeil MM, Nash SL,Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997[J]. Clin Infect Dis,2001,33(5):641-647.
[2] Tekaia F, Latge JP. Aspergillus fumigatus:saprophyte or pathogen[J]? Curr Opin Microbiol, 2005,8(4):385-392.
[3] Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species:a hospital-based survey of aspergillosis[J]. Clin Infect Dis, 2001, 33(11):1824-1833.
[4] 刘伟,李若瑜. 抗真菌药物治疗发展趋势[J]. 中国处方药, 2004,(3):59-64.
[5] Spitzer M, Robbins N, Wright GD. Combinatorial strategies for combating invasive fungal infections[J]. Virulence, 2017,8(2):169-185.
[6] Roemer T,Krysan DJ. Antifungal drug development:challenges, unmet clinical needs, and new approaches[J]. Cold Spring Harb Perspect Med, 2014,4(5):a019703.
[7] Patterson TF, Thompson GR Rd, Denning DW, et al. Practice Guidelines for the diagnosis and management ofaspergillosis:2016 Update by the infectious diseases society of america[J]. Clin Infect Dis, 2016,63(4):e1-e60.
[8] Shapiro RS, Robbins N, Cowen LE. Regulatory circuitry governing fungal development, drug resistance, and disease[J].Microbiol Mol Biol Rev, 2011, 75(2):213-267.
[9] Ostrosky-Zeichner L, Casadevall A, Galgiani JN, et al. An insight into the antifungal pipeline:selected new molecules and beyond[J]. Nat Rev Drug Discov, 2010, 9(9):719-727.
[10] Vincent BM, Lancaster AK,Scherz-Shouval R, et al. Fitness trade-offs restrict the evolution of resistance to amphotericin B[J]. PLoS Biol, 2013, 11(10):e1001692.
[11] Denning DW.Echinocandin antifungal drugs[J]. Lancet,2003,362(9390):1142-1151.
[12] Arendrup MC, Perlin DS. Echinocandin resistance:an emerging clinical problem[J]? Curr Opin Infect Dis,2014,27(6):484-492.
[13] Baym M, Stone LK, Kishony R. Multidrug evolutionary strategies to reverse antibiotic resistance[J]. Science, 2016, 351(6268):aad3292.
[14] Wood KB, Wood KC, NishidaS,et al. Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells[J]. Cell Rep, 2014,6(6):1073-1084.
[15] Onyewu C, Blankenship JR, Del Poeta M, et al. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei[J]. Antimicrob Agents Chemother,2003,47(3):956-964.
[16] ToewsML, Bylund DB. Pharmacologic principles for combination therapy[J]. Proc Am Thorac Soc,2005,2(4):282-289,290-291.
[17] Cokol M, Chua HN, Tasan M, et al. Systematic exploration of synergistic drug pairs[J]. Mol Syst Biol,2011,7:544.
[18] Polak A. Synergism of polyene antibiotics with 5-fluorocytosine[J]. Chemotherapy, 1978,24(1):2-16.
[19] Yamamoto Y,Maesaki S, Kakeya H, et al. Combination therapy with fluconazole and flucytosine for pulmonary cryptococcosis[J]. Chemotherapy, 1997, 43(6):436-441.
[20] Perea S, Gonzalez G, Fothergill AW, et al. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles[J]. J Clin Microbiol,2002,40(5):1831-1833.
[21] Shalit I, Shadkchan Y, Samra Z, et al. In vitro synergy of caspofungin and itraconazole against Aspergillus spp.:MIC versus minimal effective concentration end points[J]. Antimicrob Agents Chemother, 2003,47(4):1416-1418.
[22] Marr KA,Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis:a randomized trial[J]. Ann Intern Med,2015,162(2), 81-89.
[23] Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies:a randomized pilot study (Combistrat trial)[J]. Cancer, 2007,110(12):2740-2746.
[24] Toews ML, Bylund DB. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models[J]. Antimicrob Agents Chemother, 2004, 48(6):2007-2013.
[25] Allan RK,Mok D, Ward BK, et al. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90:evidence that coumarin antibiotics disrupt Hsp90 dimerization[J]. J Biol Chem, 2006,281(11):7161-7171.
[26] Lamoth F, Juvvadi PR, Gehrke C, et al. In vitro activity of calcineurin and heat shock protein 90 inhibitors against Aspergillus fumigatus azole-and echinocandin-resistant strains[J]. Antimicrob Agents Chemother, 2013. 57(2):1035-1039.
[27] Lamoth F, Juvvadi PR, Fortwendel JR, et al. Heat shock protein 90 is required for conidiation and cell wall integrity in Aspergillus fumigatus[J]. Eukaryot Cell, 2012,11(11):1324-1332.
[28] Lamoth F, Juvvadi PR, Gehrke C, et al. Transcriptional activation of heat shock protein 90 mediated via a proximal promoter region as trigger of caspofungin resistance in Aspergillus fumigatus[J]. J Infect Dis, 2014, 209(3):473-481.
[29] Cowen LE. Hsp90 orchestrates stress response signaling governing fungal drug resistance[J].PLoS Pathog, 2009,5(8):p. e1000471.
[30] Hodgetts S, Nooney L, Al-Akeel R, et al. Efungumab and caspofungin:pre-clinical data supporting synergy[J]. J Antimicrob Chemother, 2008. 61(5):1132-1139.
[31] Kontoyiannis DP, Lewis RE, Osherov N, et al. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species[J]. J Antimicrob Chemother, 2003,51(2):313-316.
[32] Steinbach WJ, Schell WA, Blankenship JR, et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus[J]. Antimicrob Agents Chemother,2004, 48(12):1664-1669.
[33] Lamoth F, Juvvadi PR, Gehrke C, et al. In vitro activity of calcineurin and heat shock protein 90 inhibitors against Aspergillus fumigatus azole-and echinocandin-resistant strains[J]. Antimicrob Agents Chemother, 2013, 57(2):1035-1039.
[34] Gao L, Y Sun. In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms[J]. Antimicrob Agents Chemother, 2015,59(11):7097-7099.
[35] Mori T,Aisa Y, Kato J, et al. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients[J]. Bone Marrow Transplant, 2009,44(6):371-374.
[36] Mori T,Aisa Y, Kato J, et al. Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients:an association with bioavailability of oral solution itraconazole[J]. Int J Hematol, 2009,90(1):103-107.
[37] Liu FF, Pu L, Zheng QQ, et al. Calcium signaling mediates antifungal activity of triazole drugs in the Aspergilli[J]. Fungal Genet Biol, 2015, 81:182-190.
[38] 陈培英,曾秋琼,孔庆涛,等. 维拉帕米增加伊曲康唑体外抗烟曲霉能力[J]. 中国真菌学杂志, 2017,12(4):203-206.
[39] Nazik H, Choudhary V, Stevens DA, et al. Verapamil inhibits Aspergillus biofilm, but antagonizes voriconazole[J]. J Fungi (Basel), 2017,3(3):50.
[40] Ramondenc I, Pinel C, Parat S, et al. Hydrocortisone, prednisolone and dexamethasone act on Aspergillus fumigatus in vitro susceptibility to itraconazole[J]. Microbios, 2001,104(407):17-26.
[41] Robbins N, Spitzer M, Yu T, et al. An antifungal combination matrix identifies a rich pool of adjuvant molecules that enhance drug activity against diverse fungal pathogens[J]. Cell Rep, 2015,13(7):1481-1492.
[42] Xu H, Li LJ, Wan Z, et al. Dexamethasone increases susceptibility of Aspergillus fumigatus to hydrogen peroxide via down-regulation of Afyap1 gene expression in vitro[J]. Chin Med J (Engl), 2011,124(22):3773-3777.
[43] Li T, Li JC,Qi Q, et al. Dexamethasone enhances invasiveness of Aspergillus fumigatus conidia and fibronectin expression in A549 cells[J]. Chin Med J (Engl), 2013,126(17):3289-3294.